1-3 of 3
Neus Villamor, PhD
Close
Sort by
Journal Articles

Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia

Neus Giménez Carabaza, B.Pharm, Rosich Laia, PhD, Schulz Ralph, MS, Higashi Morihiro, MD, Marta Aymerich, Neus Villamor, PhD, Julio Delgado, MD, Manel Juan, MD, Monica Lopez-Guerra, PhD, Elias Campo, Martina Seiffert, PhD, Dolors Colomer, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2650.
https://doi.org/10.1182/blood-2018-99-115999
Published: 2018
Journal Articles

The Novel HSP90 Inhibitor IPI-504 Synergizes with Bortezomib in Mantle Cell Lymphoma Cells by Targeting Both NF-kappaB Signaling and Unfolded Protein Response and Leading to Increased Mitochondrial Apoptosis.

Gael Roue, PhD, Patricia Perez-Galan, PhD, Monica Lopez-Guerra, BS, Neus Villamor, PhD, MD, Elias Campo, PhD, MD, Dolors Colomer, PhD
Journal: Blood
Blood (2007) 110 (11): 1601.
https://doi.org/10.1182/blood.V110.11.1601.1601
Published: 2007
Journal Articles

The Small Molecule Pan-Bcl-2 Inhibitor GX15-070 Induces Apoptosis In Vitro in Mantle Cell Lymphoma (MCL) Cells and Exhibits a Synergistic Effect in Combination with the Proteasome Inhibitor Bortezomib.

Patricia Perez Galan, PhD, Gael Roue, PhD, Neus Villamor, PhD, MD, Elias Campo, PhD, MD, Dolors Colomer, PhD
Journal: Blood
Blood (2005) 106 (11): 1490.
https://doi.org/10.1182/blood.V106.11.1490.1490
Published: 2005